title: Cyclosporine in severe childhood atopic dermatitis: a multicenter study.
abstract: BACKGROUND
  Severe atopic dermatitis (AD) remains difficult to treat. Cyclosporine is effective in adults but has not previously been investigated in children with AD.
  
  
  OBJECTIVE
  The aims were to investigate the efficacy, safety, and tolerability of cyclosporine in severe refractory childhood AD.
  
  
  METHODS
  Subjects 2 to 16 years of age were treated for 6 weeks with cyclosporine, 5 mg/kg per day, in an open study. Disease activity was monitored every 2 weeks by means of sign scores, visual analogue scales for symptoms, and quality-of-life questionnaires. Adverse events were monitored. Efficacy and tolerability were assessed with five-point scales.
  
  
  RESULTS
  Twenty-seven children were treated. Significant improvements were seen in all measures of disease activity. Twenty-two showed marked improvement or total clearing. Quality of life improved for both the children and their families. Tolerability was considered good or very good in 25 subjects.
  
  
  CONCLUSIONS
  Cyclosporine may offer an effective, safe, and well-tolerated short-term treatment option for children with severe AD.
authors.affiliation: Department of Dermatology, Walsgrave Hospital, Coventry, U.K.
authors.forename: J
authors.initials: J
authors.lastname: Berth-Jones
authors.forename: A Y
authors.initials: AY
authors.lastname: Finlay
authors.forename: I
authors.initials: I
authors.lastname: Zaki
authors.forename: B
authors.initials: B
authors.lastname: Tan
authors.forename: H
authors.initials: H
authors.lastname: Goodyear
authors.forename: S
authors.initials: S
authors.lastname: Lewis-Jones
authors.forename: M J
authors.initials: MJ
authors.lastname: Cork
authors.forename: S S
authors.initials: SS
authors.lastname: Bleehen
authors.forename: M S
authors.initials: MS
authors.lastname: Salek
authors.forename: B R
authors.initials: BR
authors.lastname: Allen
authors.forename: S
authors.initials: S
authors.lastname: Smith
authors.forename: R A
authors.initials: RA
authors.lastname: Graham-Brown
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002214:Capsules; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D011788:Quality of Life; D012074:Remission Induction; D012449:Safety; D012996:Solutions
chemical_list: D000893:Anti-Inflammatory Agents; D002214:Capsules; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D012996:Solutions; D016572:Cyclosporine